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2

Immune checkpoint inhibitors (ICIs) have led recent advances in the ﬁeld of
cancer immunotherapy improving overall survival in multiple malignancies with
abysmal prognoses prior to their introduction. The remarkable efﬁcacy of ICIs is
however limited by their potential for systemic and organ speciﬁc immunerelated adverse events (irAEs), most of which present with mild to moderate
symptoms that can resolve spontaneously, with discontinuation of therapy or
glucocorticoid therapy. Cardiac irAEs however are potentially fatal. The
understanding of autoimmune cardiotoxicity remains limited due to its
rareness. In this paper, we provide an updated review of the literature on the
pathologic mechanisms, diagnosis, and management of autoimmune
cardiotoxicity resulting from ICIs and their combinations and provide
perspective on potential strategies and ongoing research developments to
prevent and mitigate their occurrence.
KEYWORDS

immune checkpoint inhibitor (ICI), Cardiotoxic adverse effect, immunotherapy, anti
PD-1 antibodies, anti CTLA-4 antibodies, anti PD-L1 therapy, Cardiotoxicities

1 Introduction
In the past few decades, advances in cancer immunotherapy have revolutionized the
management of metastatic and advanced-stage malignancies, improving survival in
multiple cancers with abysmal prognoses prior to their introduction. On the frontline of
these advances are the immune checkpoint inhibitors (ICIs), known to target immune
checkpoints, which are critical immune system regulators that can dampen an immune
response to a stimulus such as an infection. These inhibitory effects are essential to maintain
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rareness of this condition makes it difﬁcult to obtain sufﬁcient
data and knowledge about these serious adverse events to form
strategies for early detection, assessment, and management. As a
result, the understanding of autoimmune cardiotoxicity remains
limited, although rapidly evolving. In this paper, we provide an
updated review of the literature on the pathologic mechanisms,
diagnosis, and management of autoimmune cardiotoxicity as a
result of ICIs and their combinations, and provide perspective on
potential strategies and ongoing research developments to prevent
and mitigate their occurrence.

self-tolerance and prevent over activity of the immune cells.
However, tumors exploit these regulatory pathways to escape T
cell-mediated antitumor immunity. Tumor cells express ligands
for immune checkpoint proteins such as the cytotoxic T
lymphocyte-associated protein 4 (CTLA-4 also known as
CD152), the programmed cell death 1 (PD-1 also known as
CD278), and Lymphocyte Activation Gene-3 (LAG-3 also
known as CD223) receptor molecules expressed on T
lymphocytes. Tumor-expressed ligands activate these receptors,
diminishing T-cell responses against the tumor. ICIs currently
utilized in clinical practice are monoclonal antibodies that target
these molecules: CTLA4, PD-1, PD-L1 (Programmed death ligand
-1) and more recently LAG-3. These therapeutics block the
receptor-ligand binding and release the inhibitory signaling,
allowing T cells to continuously recognize and attack Tumor
cells. The survival beneﬁt of ICIs has been demonstrated in
multiple randomized clinical trials, making them a mainstay
therapy for various tumors. However, they are not without
trade-offs. The remarkable efﬁcacy of ICIs is limited by their
potential autoimmune and inﬂammatory side effects known as
immune-related adverse events (irAEs). IrAEs occur in about twothirds of ICIs recipient requiring cessation of therapy in nearly 40
percent of patients (1). Autoimmune toxicities involve multiple
organ systems such as the skin, gastrointestinal tract, liver, lungs,
and endocrine system. Fortunately, most systemic, and organspeciﬁc irAEs present with mild to moderate symptoms that can
resolve spontaneously, with discontinuation of therapy or
glucocorticoid therapy. In contrast to other organ-speciﬁc
IrAEs, cardiotoxicities are rare, albeit with a high case fatality
when they occur (1, 2). For example, the incidence of myocarditis
in patient receiving ICI therapy ranges from 0.04% to 1.14%but
with an associated mortality of 25% to 50% (3, 4). The potentially
fatal outcome of cardiac irAEs warrant prompt intervention with
supportive care and glucocorticoid therapy. Unfortunately, the

2 Immune checkpoint inhibitors
There are at least nine US Food and Drug Administrationapproved ICIs as of early 2022. These include an anti-CTLA4
monoclonal antibody (Ipilimumab); four PD-1 blocking
monoclonal antibodies (Nivolumab, Pembrolizumab,
Cemiplimab, and Dostarlimab); and three anti-PD-L1
antibodies (Atezolizumab, Durvalumab, and Avelumab) and
one LAG-3 antibody (Relatlimab). Table 1 shows clinical
indications of each ICI approved by the FDA. Tremelimumab,
an anti CTLA-4 monoclonal antibody has an orphan drug
designation and is currently under investigation as a
combination regimen with other ICIs (clinicaltrial.gov). In
addition, some newer anti-PD-1 ICIs, such as Sintilimab,
Tislelizumab, Toripalimab, and Camrelizumab, which the
National Medical Product Administration of China has
approved, are currently undergoing Phase II/III testing. Some
emerging anti-PD-L1 currently under investigation include
Cosibelimab, KN035, CA-170, BMS-986189, etc. (5) .
All ICIs exert their antitumor activity by reversing the T cell
tolerance towards tumor cells that is mediated by their
checkpoint proteins. The mechanism of their toxicities,

TABLE 1 Current FDA approved Immune Checkpoint Inhibitors and their indications.

Drug

Target

Ipilimumab

CTLA-4

Melanoma, colorectal cancer, renal cell carcinoma

Nivolumab

PD-1

Melanoma, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Small cell lung cancer, Hodgkin’s
lymphoma, Hepatocarcinoma, colorectal cancer

Pembrolizumab PD-1

FDA Indication

FDA
approval
Year
2011

Melanoma, non-small cell lung cancer, non-squamous cell lung cancer, renal cell carcinoma, classic Hodgkin's lymphoma,
gastric or gastroesophageal junction adenocarcinoma, urothelial carcinoma, cervical cancer, large B-cell lymphoma, Merkel
cell carcinoma

2014

Cemiplimab

PD-1

Cutaneous squamous cell carcinoma

2018

Dostarlimab

PD-1

Recurrent Endometrial cancer

2021

Avelumab

PD-L1

Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma

2015

Atezolizumab

PD-L1

Urothelial carcinoma, non-small cell lung cancer, breast cancer, non-squamous non-small cell lung cancer, small-cell lung
cancer

2016

Durvalumab

PD-L1

Urothelial carcinoma, non-small cell lung cancer

2016

Relatlimab

LAG-3

Advance and metastatic melanoma

2022
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CTLA-4 within the T cells, which is contained within intracellular
vesicles of naive T cells and is then transported to the cell surface
and expressed as a membrane molecule. The membrane-bound
CTLA-4 signals to dampen and maintain a controlled level of T
cell activation. T cells stimulated in peripheral tissues mainly
express PD-1 rather than CTLA-4. Unlike CTLA-4, PD1
expression is upregulated transcriptionally at the mRNA level in
response to inﬂammatory signals (such as IFN-g) that are
produced by activated T cells (7).
CTLA-4 4 is a CD28 homolog with a stronger binding
afﬁnity for B7 that CD28. In the later phases of an immune
response, membrane-bound CTLA-4 interacts with the B7
molecules on APCs, blocking their interaction with CD28 and
thereby decreasing the T cell activation state which can render
the cells anergic. Similarly, PD-1 binds to ligand PD-L1 and PDL2 on the APCs to inhibit T-cell reactivity. Excessive induction
of PD-1 on T cells in the setting of chronic inﬂammation and
antigen exposure have been observed to cause T cell anergy.
Figure 1 shows the CD28/CD80, CTL4/CD80 and PD1/PDL1
inhibitory ligand interaction. LAG-3 inhibits activation of T cells
in a similar fashion to CTLA-4 and PD-1. It is co-expressed with
PD-1 in activated T cells, natural killer (NK) cells and APCs with
its main ligand is the MHC class II, to which it binds in place of
CD4 (a receptor of TCR) to dampen T cell activation (11, 12) .
These dampening effects are needed in normal physiologic
conditions to prevent T cell over-activity and maintain selftolerance during a T cell response to invading pathogens and
other antigen sources. However, tumors exploit these regulatory
pathways by expressing these inhibitory ligands thereby
interfering with the ability of T lymphocytes to direct antitumor immunity. These inhibitory processes can be reversed by
ICIs to promote cancer immunotherapy. Anti CTLA-4, PD-1/L1
and LAG-3 antibodies restore the activity of anti-tumor T cells
through blocking CTLA-4/B7, PD1/L2-L2, and LAG-3/MHC
class II interactions respectively. However, the precise
understanding of the immunostimulatory mechanisms of
various ICIs remain under investigation. For example, recent
pre-clinical studies implicating CTLA-4 as an intrinsic positive
regulator of regulatory T cell (Treg) as opposed to merely a
negative regulator of T effector cells are noteworthy (13) and
LAG3 blockade have also been shown to interfere with the
suppressive activity of Treg cells (11).

including cardiac toxicity, relates to this process. Thus,
understanding T cell activation and their inhibition is needed
to understand ICIs toxicities.

2.1 Modulators of T lymphocyte
activation and tolerance
T lymphocytes serve as one of the prime mediators of the
adaptive immune response against tumors. T cell immune
checkpoint receptors are a wide variety of molecules found on T
cells that are known to modulate the signaling pathways involved in
the activation of antigen-speciﬁc, including anti-tumor responses
(6, 7) . Activating T cell receptors include the T cell receptor
complex and costimulatory molecules such as CD28, OX40, GITR
(Glucocorticoid-induced TNF receptor family-related protein),
CD137, CD27, HVEM (herpesvirus entry mediator). Inhibitory
T-cell receptors that mitigate against T cell activity include but are
not limited to CTLA-4, PD-1, LAG-3 (lymphocyte activation gene3), TIM-3 (T cell immunoglobulin and mucin domain-containing
protein 3), BTLA (B- and T-cell lymphocyte attenuator), and
VISTA (V-domain Ig Suppressor of T-cell Activation) and the
TIGIT (T cell immunoglobulin and ITIM domain). The capacity to
develop an immune response is largely a consequence of the balance
of stimulatory versus inhibitory signaling which can result in
autoimmunity, as seen in cardiac pathologies following ICI
treatment. There are other lesser understood intracellular
metabolic pathways such as the indoleamine 2, 3-dioxygenase
(IDO), and arginase in tumors and myeloid cells that also play a
critical role in activating immune cells (8). More also, some other
immune checkpoints are now known to play a critical role in the
modulation of other subsets of immune cells aside of T cells (e.g.,
CD40 for B cells and TIGIT for NK cells) (9, 10). However, the
current clinically utilized ICIs exploit the membrane-bound
immune checkpoint proteins (CTLA-4, PD-1, PD-L1, and the
m o r e r e c e n t L A G - 3 ) . C a r d i ot ox i c i t i e s f r o m t he s e
immunotherapeutic are, therefore, our focus in this review.

2.2 Mechanism of immune
checkpoint inhibition
T lymphocyte activation involves the following steps. First,
antigen-presenting cells (APCs) process antigens to load antigenic
peptides onto their major histocompatibility complex (MHC)
molecules for recognition by a T cell that displays a cognate T
cell receptor (TCR) and a co-stimulatory CD28 receptor for B7-1
(CD80)/B7-2(CD86) expressed by the APC (7). This primarily
occurs either in lymphoid tissues for priming or peripheral tissues
for secondary responses. In lymphoid tissue, T cells are activated
when their TCRs bind to their cognate MHC-peptide complex
presented by APCs in conjunction with concurrent CD28 binding
to B7-1/B7-2. This initial response to antigen causes induction of
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2.3 Clinical beneﬁt of immune
checkpoint inhibition
Anti CTL4-A therapy: Ipilimumab prolonged overall
survival (OS) in patients with stage III or IV melanoma in a
clinical trial, leading to its approval in 2011 (14). A combination
therapy of Ipilimumab and Nivolumab, which targets PD-1, was
subsequently approved for melanoma following data from the
Checkmate 067 trial, which demonstrated an OS beneﬁt for the
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FIGURE 1

T cell activation and inhibitory receptors-ligand interactions involving TCR/MHC class II. CD28/D80. CTLA-4/CD80 and PD1/PD-L1.

standard of care in the KEYNOTE-407 and KEYNOTE-042
trial (NSCLC) (32, 33) KEYNOTE 181 (Esophageal cell
carcinoma) (34), KEYNOTE-158 (metastatic small cell lung
cancer) (35), KEYNOTE-426 (Renal cell carcinoma) (36),
KEYNOTE-224 (Hepatocellular carcinoma), KEYNOTE-017
(Merkel cell carcinoma) (37), KEYNOTE-170 (B-cell
lymphoma) (38), KEYNOTE-158 (Cervical cancer) (35) (39),
KEYNOTE-059 (Gastric and gastroesophageal junction cancer)
(39), KEYNOTE-158(MSI-h dMMR cancers) (40), KEYNOTE048 (Head and neck cancers) (41), KEYNOTE-087 (Hodgkin
lymphomas) (42), KEYNOTE-006 (Melanoma) (14), and
KEYNOTE-045 (Urothelial cancers) (43).
Anti PD-L1 therapy: Atezolizumab improve OS in the
IMpower150 trial, as ﬁrst-line treatment for metastatic NSCLC
with no EGFR/ALK mutation when used in combination with
standard chemotherapy than standard chemotherapy alone (44).
Other trials with demonstrated superiority of PD-LI inhibitors
and standard verse standard of care alone include the
IMvigor210 trial for locally advance and metastatic urothelial
cancers (45), Impassion-130 trial for triple negative breast cancer
(46), IMpower133 for extensive stage small cell lung cancer (47).
Avelumab demonstrated superiority in the JAVELIN trials (48)
and Durvalumab in the PACIFIC trials (49).
Anti-LAG-3 therapy: Relatlimab in combination with
Nivolumab showed an improved 12 months median progression
free survival (47.7% vs 36%) in patients with previously untreated
metastatic or unresectable melanoma when compared to
Nivolumab monotherapy in the RELATIVITY-07 trail (50).

combination therapy versus Ipilimumab monotherapy (15). It’s
indication further expanded to include renal cell carcinoma after
the Checkmate 214 trial showed signiﬁcant improvement in OS
and progression-free survival (PFS) (16, 17). In the Checkmate
227 and Checkmate 9LA, Nivolumab plus ipilimumab as ﬁrstline treatment improved OS compared to chemotherapy in nonsmall cell lung cancer (NSCLC) (18, 19). The newer antiCTL4A-4 Tremelimumab was granted an orphan drug
designation after showing modest clinical efﬁcacy for treating
malignant mesothelioma in a phase II trial. Tremelimumab,
however, failed to meet clinical endpoints in the DETERMINE
trial (20, 21). Tremelimumab is currently tested for other tumor
types and in combination therapy (22).
Anti PD-1 therapy: Nivolumab was approved by the FDA in
2014 based on the CheckMate-037 trial, which demonstrated an
improvement in overall response rate with Nivolumab against
standard-of-care chemotherapy in patients with advanced and
progressing unresectable/metastatic melanoma (23). Its clinical
use in melanoma has expanded since 2014 based on the
Checkmate 067 and Checkmate 238, which demonstrated OS
and PFS beneﬁts combined with Ipilimumab (15, 24). Similar
efﬁcacy has been demonstrated for other disease sites. These
include Checkmate 17/57 and CheckMate-032 trial (NSCLC)
(25, 26) Checkmate-214 (Renal cell carcinoma), (17, 27)
Checkmate-205 (Hodgkin Lymphoma), (28) Checkmate 275
(Urothelial carcinoma), (29) Checkmate-040 (hepatocellular
carcinoma) (30) and Checkmate-141 (head and neck tumors).
(31) Pembrolizumab combination superiority over prior
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TABLE 2 Select cardiac pathology as a percentage of overall cardiac irAEs reported on Vigibase for each ICIs as of 2022(VigiAccess, July 2022).

Anti C TL4A

Anti PD-1

Anti PD-L1

Anti-LAG3

Select Cardiac irAEs

Ipilimu mab

Nivolu
mab

Pembrolizu
mab

Atezolizu
mab

Aveluma
b

Cemipli
mab

Dostarlim
ab

Durvalum
ab

Relatlimab

Reporting timeline

2009-2002

2014-2022

2015-2022

2015-2022

20152022

2018-2022

2019-2022

2014-2022

2017-2022

2

2

2

2

3

3

5

3

6

Myocarditis (%)

22.7

20.7

19.9

15.8

20

27.3

14.2

21.4

33.3

Atrial Fibrillation (%)

16.3

11.2

9.7

15.4

14.4

7.6

7.1

11.6

n/a

Myocardial Infarction (%)

6.1

6.5

6.2

7.9

2.3

6.1

7.1

5.8

11.1

Cardiac arrest (%)

6.6

5.0

5.0

5.8

10.0

3.0

21.4

7.1

n.a

Cardiac Failure (%)

5.6

8.3

8.3

9.1

10.0

16.7

0.0

5.4

11.1

Cardiac irAEs as percent of all
irAEs (%)

reporting, reporting bias, and a lack of information on population
exposed to the drug. The risk associated with a drug is therefore
difﬁcult to quantify accurately in these databases (53–55).
Vigibase do not provide data on fatality. Wang and
colleagues in a 2018 meta-analysis of 112 trials involving
19,217 patients showed toxicity-related fatality rates of 0.36%
for anti-PD-1, 0.38% for anti-PD-L1, 1.08% for anti-CTLA-4),
and 1.23% for combined anti-PD-1/PD-L1 plus CTLA-4 therapy
(2). A 6 year (2011-2017) analysis of the Danish registry
demonstrated an absolute risks for cardiac irAEs of (6.6–9.7%)
with anti-PD1 and anti-CTL4 therapy, signiﬁcantly higher than
reports from pharmacovigilance studies (56). However, this
study only included patients with malignant melanoma and
lung malignancies which are generally considered high risk
malignancies for irAEs. Moreover, the determination of what
entails a cardiac irAE, which is not consistent between reports,
may explain some discrepancy between various data repositories
(57). Evidently, mortality is more frequent with combination
PD-1/CTLA-4 blockade (58). There are currently no mortality
data for anti-LAG-3 therapy and Vigibase cardiotoxicity data on
Relatlimab should be characterized with caution due to a low
sample of only 66 adverse events. Additional large prospective
studies are needed to provide more precise estimates of the
actual incidence and fatality rates of cardiotoxicity arising from
ICI immunotherapy.

3 Cardiac irAEs of immune
checkpoint inhibitors
Cardiac IrAEs have been reported in association with anti
CTLA-4, anti PD-1, and their combinations. Reported cardiac
toxicity is diverse, involving various cardiac tissues.

3.1 Epidemiology
The exact incidence of cardiac IrAEs resulting from ICI
therapy have been difﬁcult to quantify as early clinical trials
testing efﬁcacy of ICIs did not routinely evaluate for changes in
cardiac function and myocardial injuries. Limited epidemiological
data can be obtained from manufacturer safety databases, the
World Health Organization (WHO) pharmacovigilance
repository, (3) the FDA Adverse Event Reporting System
(FAERS) database, and retrospective studies including metaanalysis of existing data and case reports. However, estimates
from each source vary signiﬁcantly. There is a possible
underestimation of the incidence of cardiac irAEs for a host of
reasons, ranging from the vagueness in its clinical presentation,
the potential overlap with other cardiovascular disease and
comorbidities, and a poor awareness of this condition (51). The
WHO database reported higher incidence of ICI irAEs likely due
to increased use of ICIs and improved recognition of their
toxicities. Data from WHO database suggests myocarditis and
arrhythmias as the most common cardiac irAEs. Table 2 shows
selected cardiac morbidities as a percentage of overall cardiac
irAEs reported on Vigibase for each ICI as of 2022. In a 2020
systematic review and meta-analysis, 0.1%-0.9% for myocarditis,
0.1%-1.0% for pericardial effusion, 0.0%-0.5% for cardiac failure,
0.3% for cardiomyopathy, 4.6% for atrial ﬁbrillation, 0.0%-0.7%
for myocardial infarction, and 0.1%-0.8% for cardiac arrest (52).
Pharmacovigilance reporting systems may be limited by under-
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4 Mechanism of ICI induced
cardiac IrAEs
The exact mechanism of ICI-associated cardiotoxicity is not
yet fully understood (59). Proposed mechanisms include: (i)
Direct destruction of cardiac tissue by deregulated, activated
autoimmune T lymphocytes; (ii) Indirect destruction of cardiac
structures by pro-inﬂammatory cytokines and other molecules
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effect against T lymphocyte-mediated cardiac injury (65).
Preclinical insights from genetic and manipulation of immune
checkpoint pathway have further bolstered this theory. For
example, PD-1 and CTLA-4 knockout mice develop rapid
lymphoproliferation and fatal T cell mediated myocarditis (66).
Cellular inﬁltration of cardiac myocytes in irAEs may also be
due to the immune polarization effects of ICIs (67) . For example,
anti-PD1 has been found to transduce immunoregulatory signals
that modulate macrophage polarization to pro-inﬂammatory
phenotype via the inhibitory effects of microRNA-34a (miR34a) on the Krüppel-like factor 4 (KLF4) signaling pathway.
Consistent with this ﬁnding, among other activities, the
transcription factor KLF4 has anti-inﬂammatory properties with
a cardiac protective effect. Xia and colleagues hypothesize that
miR-34a mediated inhibition of the KLF4 pathway leading to
inﬂammatory macrophage activity may account for the cellular
inﬁltration and destruction of cardiac tissues seen in ICI therapy.
In their in-vivo experiment, anti-PD1 treatment was shown to
induce polarization of pro-inﬂammatory macrophages
accompanied by increased MicroRNA-34a expression and
decreased expression of KLF4, resulting in cardiac injury 67).

released by ICI deregulated T lymphocytes and the cells that they
activate, such as macrophages; (iii) Recognition of cardiac selfantigens by autoantibodies to promote cell-mediated
cardiotoxicity. These mechanisms can involve single or
multiple cardiac structures resulting in pathologies.

4.1 Direct cellular destruction of
cardiac tissue
Cardiac cells, like APCs and certain cancer cells, are now
known to activate CTLA-4 and PD-1/PD-L1 pathways to
maintain self-tolerance of cardiac structures during T
lymphocyte responses to stress and stimulatory antigens under
physiological conditions (60) (see Figure 2). CTLA-4 and PD-/
PD-L1 blockade likely interrupt this immunologic homeostasis
thereby causing auto-immune cardiac toxicity mediated by
deregulated T-lymphocytes. Evidence for this theory stem
from histological and immunohistochemical analyses
demonstrating membrane and cytoplasmic expression of PDL1 in injured cardiac tissue (61, 62). PD-L1 expression is higher
in cardiac tissue samples from patients with ICI-associated
myocarditis, which is consistent with lymphocytic myocarditis
as histologically characterized by myocardial inﬁltration of
macrophages and CD4+/CD8+ T lymphocytes (63, 64). In a
preclinical study, Grabie et al. demonstrated the expression of
PD-LI on cardiac endothelium which has a cardio-protective

4.2 Cardiac antigen immune reactivity
There is ample of evidence to suggest the existence of
common T-cell receptors or epitopes between certain cardiac

FIGURE 2

PO-L1 expression on cardiac tissues confers protection from activated T cell via P0-1/PO-L1 inhibition of T cells. This inhibition is lost in ICI
therapy resulting in an autoimmune T lymphocyte destruction of cardiac tissues.
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species (ROS) 18. These cytokines and radicals can have
cytotoxic effects on cardiac myocytes, resulting in arrhythmias,
conduction abnormalities, impaired contractility, and other
cardiac anomalies (78, 79). CRS is however less common with
ICIs when compared with other novel cancer
immunotherapeutic such as the chimeric antigen receptor
(CAR) T cell therapy (80). Findings from Vigibase data on
adverse drug reactions suggests CRS incidence to range from
0.05% to 0.14% for ICIs, and more common with anti-PD1/PDL1 combination therapies (77).

myocytes and tumor (68, 69). This shared antigen theory is
supported by the relatively early onset of myocarditis observed
after initiating ICI therapy in a select group of patients. It is quite
possible that a pre-existing molecular mimicry that allows an
immune evasion for these cardiac cells in a similar fashion to the
tumors become disrupted, predisposing these patients to the
development of myocarditis when treated with ICIs (69).
However, multiple questions remain to be answered with
respect to this hypothesis such as the nature of these epitopes,
how they elicit an immune response, and how immune effectors
are targeted to cardiac tissue. While these questions abound,
recent translational studies suggest a second hit may be
necessary to initiate cardiac immune reactivity (70). In a study
by Michel and colleagues, mice models with transplanted tumors
developed left ventricular (LV) dysfunction with the initiation of
ICI therapy. In contrast, LV dysfunction was undetectable in
tumor-free mice receiving the same ICI therapy. This ﬁnding has
led to the postulation of a second hit theory, which argues that a
form of systemic stress induced by the presence of the tumor
may be required to initiate the cardiac immune reactivity in
predisposed patient (70). In addition, anti- PD-1 therapy is now
recognized to drive the development of auto-antibodies against
cardiac speciﬁc proteins. Okazaki et al. demonstrated that mice
deﬁcient in PD-1 develop autoimmune dilated cardiomyopathy
with production of high-titer autoantibodies against the cardiacspeciﬁc protein cardiac troponin I (cTnI) (71, 72). Further
investigation demonstrates that the anti cTnl autoantibodies
induces heart dysfunction and dilation through chronic
stimulation of Ca2+ inﬂux into cardiomyocytes (71, 72). Other
auto-antibodies induced by ICI therapy with the potential to
initiate or escalate cardiac irAEs include antibodies reactive with
acetylcholine receptors, striated muscle cells, mitochondria,
alanyl-tRNA synthetase, signal recognition particle (SRP), and
3-hydroxy-3-methylglutaryl-coenzyme A reductase (73–76).
These auto-antibodies have been associated with myocarditis,
primarily mediated through cross reactivity with cardiac striated
muscle antigens and/or inducing antibody-dependent cellular
cytotoxicity (ADCC) (73–76).

4.4 Dysregulation of myocardial
metabolism
Michel and colleagues propose a metabolic pathway leading
to myocardial dysfunction due to anti-PD1 therapy based on
substrate analysis in experimental model (see Figure 4) (70, 81) .
Molecular analysis of cardiomyocytes from mice treated with
anti-PD1 therapy shows metabolic disturbances including a
reduction in metabolites such as carnitine/acylcarnitine carrier
protein, acyl-CoA dehydrogenase, acyl-CoA synthetase pyruvate
dehydrogenase kinase 4 (PDK-4), and pyruvate carboxylase with
a concomitant increase in beta-oxidation substrates, cardiac
TNF-alpha and 1,3-bisphosphoglyceric acid (70). These
measures indicate changes in lipid and glucose metabolism
capable of altering oxidative phosphorylation, mitochondrial
function, plasma membrane permeability, and other cellular
functions, ultimately leading to cell death. This dysregulation
of myocardial metabolism seen with ICI therapy is likely to be a
downstream effect of the immune/inﬂammatory pathologies
caused by the cardiac irAE mechanisms already discussed
above but may also drive currently underappreciated aspects
of the disease process.

5 Clinical risk factors for ICI induced
cardiac IrAEs
Identiﬁcation of patients at risk for ICI induced IrAEs is
difﬁcult and an ongoing area of research. A risk predictive
model is needed to provide a basis for the clinical use of ICIs, as
well as a guide for the prompt management of ICI toxicities.
Identiﬁed patient-related risk factors for cardiac IrAEs include
pre-existing cardiovascular diseases, co-morbidities (such as
hypertension and diabetes mellitus), age, sex, underlying
autoimmune diseases, opportunistic pathogens, medications,
tumor-related factors, and genetic predisposition. Therapyrelated risk factors include the use of combinatorial cancer
therapy (such as irradiation, chemotherapy, targeted therapies,
and other ICIs or immunotherapies), speciﬁc ICIs and
their dosage.

4.3 ICI induced cytokines release
The production of pro-inﬂammatory cytokines is
upregulated by therapies that activate certain T cell subsets,
leading to a constellation of non-speciﬁc inﬂammatory processes
known as the cytokine release syndrome (CRS) (77, 78) (see
Figure 3). In CRS, T cells, NK cells, APCs and endothelial cells,
release a variety of cytokines at supraphysiologic levels (77)
Interleukin-6 (IL-6) is most implicated in CRS (77). Other
molecules associated with CRS include interferon-gamma
(IFN-g), tumor necrosis factor-alpha (TNFa); nitric oxide
(NO); nitric oxide synthase (NOS); and reactive oxygen
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FIGURE 3

Pro-inﬂammatory cytokines upregulated by ICI therapies may activate certain T cell subsets, leading to a constellation of non-speciﬁc
inﬂammatory processes known as the cytokine release syndrome.

Females have been reported to be associated with higher rates
of IrAEs although this phenomenon lacks mechanistic
explanations (82). Age group and BMI as a risk factor have
yielded conﬂicting reports in retrospective studies (82). One
retrospective study demonstrated an association of ICI IrAEs

5.1 Patient related risk factors
Several possible baseline risk factors proposed for IrAEs in
general have little prospective evidence to support their
association with the development of cardiac speciﬁc IrAEs.
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FIGURE 4

Metabolic response to anti-PD1 therapy based on substrate analysis in experimental model (70, 81).

with patient BMI. IrAEs were found to increase by 9% with every
BMI increase by 1 kg/m2 (83). The occurrence of certain
toxicities varies depending on the type of malignancy and/or
pathway blocked. Patients with lung cancer are notable for
increased odds of irAEs or irAEs requiring hospital admission
when compared to patients with other malignancies (melanoma
OR (odd ratio): 0.70, renal cell carcinoma OR: 0.71, other
malignancy OR: 0.50) (84). Hazard ratios of 2.14 (95% CI
1.50-3.05) in patients with lung cancer and 4.30 (1.38-13.42)
and 4.93 (2.45-9.94) have been demonstrated in patients with
malignant melanoma treated with anti-PD1 and anti-CTLA-4,
respectively (56). Furthermore, a circulating neutrophil/
lymphocyte ratio greater than 3.0 at the time of starting
treatment has been correlated with a lower risk of IrAEs (83).
Pre-existing auto-immune disorders may also increase risk for
ICI IrAEs as reported in multiple case series (85). However, this
remains unclear. Baseline cardiac pathologies is also a risk factor.
In the Phase III Javelin Renal 101 trial of ICI and targeted
therapy combination, patients with elevated baseline troponin
suggestive of baseline cardiac pathologies and autoimmune
diseases were shown to have higher risk of major cardiac
irAEs when compared to patients with low baseline troponin
values (86).

Frontiers in Oncology

5.2 Therapy-related risk factors
5.2.1 Combinatorial therapy
ICI combinations, either with other ICIs or with other
oncologic therapies such as chemotherapy, radiation therapy,
and targeted therapy have signiﬁcantly improved prognosis for
many cancers. The cardiac irAEs of combination regimens
involving ICIs and other conventional therapies is an active
area of investigation as toxicities inherent to individual therapies
may amplify with various combinations.
i. Dual ICI therapy: Clinical beneﬁts of combination ICI
have been demonstrated in multiple randomized
clinical trials. However, this often comes at a cost of
exacerbated treatment toxicities. In a recent database
review of over 14,000 patients who received ICI in the
United Sates, combination ICIs (anti-PD-1/PD-L1 and
CTLA-4) were associated with a more than two fold
increase in odds of developing IrAEs requiring hospital
admission which were particularly noticeable in lung
malignancies (84). In this study, incidence of irAEs
warranting hospital admission was 3.3% for patients
treated with anti-PD-1 antibodies, 1.1% for patients

09

frontiersin.org

Irabor et al.

10.3389/fonc.2022.940127

TABLE 3 Current Pathology Grading criteria for ICI induced myocardial inﬂammation.

3a. Palaskas et.al Grading Criteria (117)
Grade

Pathologic features
Negative

0
1- Myocardial inﬂammation

Multifocal inﬂammatory inﬁltrates without overt cardiomyocytes loss by light microscopy

1A

Mild inﬂammatory cell score by immunohistochemistry (10-20 inﬂammatory cells/ high power ﬁeld)

1B

At least moderate inﬂammatory cell score by immunohistochemistry
(>20 inﬂammatory cells/ high power ﬁeld)

2- Deﬁnite myocarditis

Multifocal inﬂammatory cell inﬁltrates (>40 inﬂammatory cells/ high power ﬁeld)

3b. Champion and Stone Grading Criteria (118)
Grade

Immunohistochemistry

Low Grade

(50 CD3+ cells/high power ﬁeld)

High Grade

>50 CD3+ cells/high power ﬁeld

therapy is an active area of research. Meta-analysis
however, demonstrates an increase in cardiac IrAEs
when a chemotherapeutic agent is combined with ICI
85
. In Hu’s study, PD-1 blockade plus chemotherapy
exhibited a signiﬁcant increase in all grades of
myocardial disease when compared with
chemotherapy alone (88). Aside from the
conventional systemic therapies, cardiac toxicity in
targeted therapies is increasingly also being
recognized. Trastuzumab (an anti-erbB2) for example
is known to cause left ventricular dysfunction and the
induction of congestive heart failure. BRAF and MEK
inhibitors can also cause a decline in left ventricular
ejection fraction (90). There is a demonstrable risk of
myocardial infarction, atrial ﬁbrillation, and QTc
prolongation with BRAF inhibitor therapy which is
theorized to be caused by a BRAF-mediated alteration
of the myocardial repolarization process (91). The
potentiation of cardiac toxicities due to treatment
with ICIs in combination with these targeted
therapeutics has yet to be explored in a clinical trial.
However, insights from pre-clinical studies
demonstrate a 3 fold increased calcium overload and
reduced viability of human cardiomyocytes treated with
the combination of Pembrolizumab and Trastuzumab
compared to cells treated with either reagent alone (92,
93). The pembrolizumab-trastuzumab combination,
when compared to monotherapy, was also noted to
increase inﬂammation affecting cardiac cells and
cardiac ﬁbrosis by enhancing the expression of NF-kB
and interleukins (93).
iii. Radiation Therapy: The effects of radiotherapy (RT) on
both tumors and its microenvironment involves a complex
manipulation of immune system. Radiotherapy has
potential to alter the tumor immune microenvironment

treated with anti-PD-L1 antibodies, 3.9% for patients
receiving anti-CTLA-4 antibodies, and 3.5% overall for
all ICI antibodies as monotherapy. However,
hospitalization rates was increased to 7.3% for
patients on combination therapy (84, 87). Hu in his
systematic review and meta-analysis of 2,551 studies
with 20,244 patients reported an increased risk of
cardiac arrhythmia with ICI combination (anti PD-1
and anti CTLA-4) therapy compared to either agent as
monotherapy (OR 3.90, 95% CI: 1.08–14.06, p = 0.603)
(88). Also, WHO database reports mortality from ICIassociated myocarditis to have an almost two fold
increase with combination ICIs (60% versus 36%)
when compared to patients who receive anti-PD-(L)1
monotherapy (58).
ii. Chemotherapy and Targeted therapies: Many
conventional chemotherapies unfortunately have
cardiotoxicities effects that can be ampliﬁed with ICIs
whether delivered concurrently or sequentially. The
hypothesized mechanisms of chemotherapy-induced
cardiotoxicity vary by agents. For example,
anthracyclines may have direct cellular toxicity via
mitochondrial damage, with cumulative myocardial
injury, resulting in both diastolic and systolic
dysfunction (89). Taxanes cause myocardial damage
via their effects on subcellular organelles, or through the
induction of massive histamine release, and are
associated with conduction disturbances and
arrhythmias (89). 5-Fluorouracil has direct toxic
effects on the vascular endothelium which can cause
spasm of coronary vessels, platelet aggregation, and
thromboxane formation, increasing thrombogenesis
and cardiac injuries. The potentiation of these
chemotherapy-associated and/or ICI-associated
cardiac IrAEs in chemotherapy-ICI combination
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TABLE 4 ASCO grading for ICI induced myocarditis is based on biomarkers, ECG, imaging and clinical presentation (120).

Grade 1
Asymptomatic

Clinical

Grade 2
Mild

symptoms

Grade 3

Grade 4

Moderate

Moderate to severe

(Symptom with

decompensation, IV

mild activity)

medication or
intervention required,
life-threatening
conditions

Abnormal

Cardiac

Abnormal

Abnormal

Abnormal

Biomarkers
ECG

Abnormal

Abnormal

Abnormal

Abnormal

TTE

–

–

LVEF <50% or

LVEF <50% or

regional wall

regional wall motion

motion
Cardiac MRI

–

–

Cardiac MRI

diagnostic or

diagnostic or

suggestive of

suggestive of

myocarditis

myocarditis

ipilimumab at a dose of 3 mg/kg and 79% (95% CI, 69-89%)
for ipilimumab at a dose 10 mg/kg (101). Another meta-analysis
of 2,551 studies including 25 clinical trials and 20,244 patients
treated for advanced melanoma show a decreased risk for all
severe IrAEs with ipilimumab at 3 mg/kg every 3 weeks;
pembrolizumab at 10 mg/kg every 2-3 weeks; and Nivolumab
at 3 mg/kg every 2 weeks when compared with ipilimumab at 10
mg/kg every 3 weeks (102). The irAEs were unspeciﬁed in this
study (102). Hu’s cardiac speciﬁc meta-analysis however did not
show any signiﬁcant difference in cardiac IrAEs between
ipilimumab at a dose of (3 mg/kg q3w) versus (10 mg/kg q3w)
(88). Nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg also
showed no increased risks of coronary artery disease compared
with a dose of ipilimumab at 3 mg/kg plus Nivolumab at 1 mg/
kg. Similarly, compared with a dose of 10 mg/kg q2w, a dose of
10mg/kg q3w PD-1 inhibitor (pembrolizumab) did not show
signiﬁcantly increase risks of cardiac failure (88). Dosage for a
combination including ICI and a different kind of
immunotherapeutic (such as CART-T) or a biologic agent is
much more complex and requires additional study at this
time (99).

to augment the antitumor effects of ICIs, speciﬁcally by
releasing cytokines, endogenous danger signals, increasing
the presentation of tumor-associated antigens by APC, and
stimulating diversiﬁcation of the anti-tumor T cell
repertoire (94). Wang and colleagues demonstrated RT
and anti-PD1 synergy to improve clinical endpoints may
result from RT overcoming PD-1 inhibitor resistance by
inducing the production of type I interferon (IFN) leading
to an enhancement of MHC class 1 expression (95, 95). Lee
and colleague showed radiation therapy at an ablative dose
can have an anti-tumor effects that are dependent on
cytotoxic T-cells (96). Other studies have observed an
abscopal effect where radiation therapy of primary tumor
could have a potent effect on non-irradiated tumor cells
(94) (94). However, combined radiotherapy and ICI may
also affect both the type and severity of immune related
toxicities, including cardiotoxicity. For example, the
combination of thoracic radiation and PD-1 blockade
can exacerbate radiation-initiated cardiac inﬂammation
and cardiotoxicity (97, 98).

5.2.1 Dosage of ICI

6 Clinical diagnosis and
management

The safety of ICIs given in combination with a variety of
other cancer agents is clearly dependent on the dosage
administered (99) . There is also evidence that this is the case
for the risk of cardiac IrAEs (100). However, establishing safe
doses for novel combination therapies involving ICIs has been
challenging in face of the limited clinical experience with their
utilization (99). In a meta-analysis by Bertrand and colleagues,
the risk of developing all irAEs was dependent on dosage, with
their incidence evaluated as 61% (95% CI, 56-66%) for
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6.1 Clinical manifestation
One main prerequisite for managing cardiac IrAEs is the
knowledge and awareness of this complication. Subtle signs and
symptoms which may become progressive need to be adequately
interpreted to initiate management and avert complications.
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elevation, atrioventricular block, ventricular arrhythmias, Twave inversions, and new Q waves anomalies (107), (103,
106). T wave changes are the most common ECG
abnormalities seen ECG changes in ICI cardiac events (107),
(103, 106). ECG should be carefully interpreted with context to
the patient as anomalies are common in the cancer patient
population which do not always indicate a cardiac irAEs.
Collecting a baseline ECG allows for recognition of any
change occurring during ICI therapy, facilitating early
diagnosis of associated cardiotoxicity (106).

Manifestations of cardiac irAEs range from a subclinical rise in
cardiac biomarker and vague symptoms such as malaise to overt
symptoms of chest pain, dyspnea, palpitations, progressive
fatigue, pre-syncope and syncope that can lead to multiorgan
failure, cardiogenic shock, and cardiac arrest. (59, 103). These
symptoms may be obscured by other non-cardiac irAEs such as
myositis, hypothyroidism, pneumonitis, or other symptoms
related to the primary malignancy or comorbid conditions.
The median time to onset of clinical manifestation of cardiac
irAEs is 6 weeks (typically 3 to 9 weeks) but can range from 2 to
54 weeks (104), typically corresponding to the period after the
ﬁrst and third infusion (105). The average time until symptoms
vary for each ICI type, cancer type, type of cardiotoxicity, and
delivery with other therapeutics (104). On literature review, the
anti-PD-L1 ICIs were found to have an earlier median time to
presentation of symptoms (1-9 weeks for Atezolizumab and
Durvalumab) (104). The anti-CTLA-A agent ipilimumab had a
longer median onset time of 10 weeks, however in combination
with nivolumab this median time was reduced to 6 weeks (104).

6.2.3 Cardiac imaging

A hallmark of ICI induced myocarditis is an increase in
serum cardiac biomarkers, notably troponin, BNP, NT-proBNP,
and CK-MB which are further discussed in the biomarker
subsection of this review.

For concerns of an acute coronary syndrome, emergency
coronary angiography may be indicated for patients presenting
with abnormal cardiac biomarkers and ECG or ischemic
symptoms. In addition, TTE could provide further insight into
motion anomalies of the myocardium and left ventricular
ejection fraction (LVEF) compromise. TTE anomalies may be
detected at later stage of ICI-associated myocarditis. Cardiac
MRI (CMR) has a diagnostic superiority to TTE because it can
identify ﬁbrosis and inﬂammation tissue characteristics in the
early course of the disease. ICI myocarditis is typically deﬁned
using the modiﬁed Lake Louise Criteria (108, 109). An analysis
of clinical, CMR, and histopathological ﬁndings of patients on
ICIs from international registries and retrospective studies
shows that T1 mapping and application of the modiﬁed Lake
Louise I or the updated Lake Louise II criteria provides
important diagnostic value and prognostic value in patients
with ICI-associated myocarditis (108, 110, 111). CMR and
echocardiographic ﬁndings of impaired global circumferential
strain, global radial strain, and global longitudinal strain in
patients with an ICI associated myocarditis have been reported
by many studies (112, 113). Other studies also showed a low
sensitivity of CMR in detecting cardiac irAEs with features such
as septal late gadolinium enhancement (LGE) seen only in 48%
of patients (114). More also, LGEs result from the changes
contrast uptake and washout patterns within the extracellular
space could be seen in most myocardial injuries and therefore
not speciﬁc for ICI-associated myocarditis (115). Further studies
are needed to characterize cardiac MRI criteria for ICIassociated toxicities.

6.2.2 Electrocardiography

6.2.4 Endomyocardial biopsy

ECG is often a ﬁrst-line test to identify patients with
suspected cardiac irAEs. A 12-lead ECG should immediately
be performed once a patient complains of chest pain,
palpitations, dizziness, dyspnea, or any other concerning
cardiac symptom (106). Abnormal ECGs have been reported
in 40–89% of patients with ICI related toxicities. ECG
abnormalities that may raise suspicion of cardiotoxicity
include abnormal PR interval, ST-segment depression and

Endomyocardial biopsy (EMB) which is gold standard for
the diagnosis of ICI myocarditis, should be considered for
patients with concerns for myocarditis based on cardiac
imaging, cardiovascularly unstable patients, and patients who
fail to respond to initial treatment with steroids. EMB could also
aid deﬁnitive diagnosis when diagnosis is in doubt. Myocardial
features identiﬁed on EMB for ICI-associated myocarditis
include interstitial ﬁbrosis, lymphocyte inﬁltration, T cells

6.2 Clinical investigation
A detailed history, review of systems, and physical exams is
required to exclude other cardiac diseases. Blood tests,
electrocardiograms (ECGs), chest X-ray, and trans-thoracic
echocardiograms (TTEs) are needed for diagnosis and
management. Laboratory tests typically include the assessment
of serum levels of cardiac troponins (including cardiac troponin I
[cTnI] and troponin T [cTnT]), creatine phosphokinase (CPK),
creatine kinase (CK), and creatine kinase-myocardial band (CKMB). Others include brain natriuretic peptide (BNP), and Nterminal pro-brain natriuretic peptide (NT-proBNP) (59, 103).
Additional testing such as stress tests, cardiac catheterization, and
cardiac MRI may be guided by the cardiologist (103).

6.2.1 Laboratory investigations
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(CD4+, CD8+), macrophage inﬁltration, and other inﬂammatory
changes (116). Palaskas and colleagues recently developed a
grading system for ICI myocarditis and myocardial
inﬂammation by pathology ﬁndings on EMB and noted a
correlation with clinical outcomes (see Table 3A) (117).
Interestingly, the Palaskas et al. study identiﬁed patients with
EMB conﬁrmed grade 1 ICI induced myocarditis as a low-risk
group that may be capable of continuing ICI therapy without
immunomodulation (117). This ﬁnding is however difﬁcult to
routinely introduce to clinical practice give the need for an EMB
for grading ICI-related myocarditis. Champion and Stone used
EMB to classify ICI-associated myocarditis based on
inﬂammatory cell accumulation in cardiac tissues into highgrade (>50 CD3+ cells/high power ﬁeld) and low-grade (≤50
CD3+ cells/high power ﬁeld) groups by EMB ﬁnding (118) (see
Table 3B). High-grade patients had a fulminant clinical disease
course leading to a hundred percent fatality, while patients with
low-grade cell accumulation had a more indolent clinical course
with a hundred percent overall survival (118). These ﬁndings
illustrate the value of EMB assessment of the extent of
inﬂammatory changes in cardiac tissue following ICI but
standardized criteria are yet to be adopted for the
histopathologic grading of ICI myocarditis (119) .

steroids were unclear in this retrospective series, the authors
recommend pulse dose steroids at 1000 mg daily, followed by 1
mg/kg daily of either oral or intravenous steroids (4, 121).
In steroid refractory cases, alemtuzumab, inﬂiximab,
tocilizumab, or rituximab and the CTLA4 agonist (abatacept) can
be considered. Caution is needed with use of inﬂiximab as it has
been associated with heart failure and is contraindicated at high
doses in patients with moderate to severe heart failure.
Plasmapheresis has also been used, with the goal of accelerating
removal of the contributing drug (as well as any potential
circulating autoantibodies). This approach is important with ICIs
because their half-lives are extremely long: 14.5 days for
Ipilimumab, 25.0 days for pembrolizumab, 26 to 27 days for
Nivolumab and 27.0 days for Atezolizumab. Supportive
management can entail inotropic therapy and even mechanical
circulatory support, including extracorporeal membrane
oxygenation, as a bridge to recovery, as has been shown in
patients who developed fulminant myocarditis with
cyclophosphamide and ICIs. Current treatment recommendations
are notably based on anecdotal evidence and the life-threatening
nature of cardiac complications.

7 Biomarkers
6.3 Treatment of ICI-induced
cardiac irAEs

Molecular biomarkers are needed to predict which patients
will experience cardiac IrAEs from ICI therapy. Several
biomarkers such as the expression of programmed cell death
ligand 1 (PD-L1), tumor mutation burden (TMB), and
microsatellite instability-high (MSI-H)/mismatch repairdeﬁciency (dMMR) have proven to be predictors for antitumor efﬁcacy of ICIs (122, 123). However there remains a
pressing clinical need for the identiﬁcation of biomarkers that
can predict toxicities as well as help ﬁlter out the patients who
may beneﬁt most from these costly therapies from those at risk
of major cardiac toxicities. There are few reports of biomarkers
for the prediction of, or early detection of IrAEs in general.
These include changes in the expression of cytokines/
chemokines, cellular markers, autoantibodies, and genes. There
is unfortunately no report describing markers selective for
cardiac speciﬁc IrAEs (124). Currently, putative biomarkers for
cardiac-speciﬁc IrAEs are limited to the serum levels of proteins
such as cardiac troponin (cTn), and myoglobin but these are
largely not selective for ICI IrAEs and not supported by
extensive clinical validation.

Treatment of ICI cardiac irAEs requires collaboration
between the oncologist and cardiologist. In all cases, empirical
treatment for ICI cardiotoxicity should be started once the
suspicion is high, even before conﬁrmatory pathologic testing
is obtained. The 2021 American Society of Clinical Oncology
Clinical (ASCO) practice guidelines recommends holding ICI
therapy starting with Grade 1 cardiac irAEs and a permanent
discontinuation of therapy for Grade 2 or higher toxicities (see
Table 4) (103). ASCO guidelines also recommend that all-grade
toxicities have early administration of high-dose corticosteroids,
typically 1-2 mg/kg of prednisone oral or intravenous depending
on symptoms (103).
An immediate transfer to a coronary care unit is recommended
for patients with elevated troponin or conduction abnormalities
(103, 120). Patients with no immediate response to low dose steroid
(1-2mg/kg) may receive high dose steroid (1 g daily intravenous
methylprednisolone) with addition of other immunosuppressive
therapy such as mycophenolate, inﬂiximab, or anti-thymocyte
globulin (103). ASCO clinical practice guidelines recommend a
steroid taper of at least 4 to 6 weeks. Aggressive initial steroid
strategy is also an option (500-1000 mg daily), especially in clinically
unstable patients (4, 121). Mahmood et al retrospectively compared
high dose versus low‐dose glucocorticoids and reports lower
adverse events in patients who received high‐dose steroids (4,
121). Although selection criteria for high‐dose versus low‐dose
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Peripheral blood count (PBC): The indices and absolute
values of peripheral blood components such as leukocytes,
neutrophils and lymphocytes and platelets have been well
established as prognostic markers for ICI responses and
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Cardiac Auto-antibodies: Okazaki and colleagues showed
that dilated cardiomyopathy in PD-1 deﬁcient mice is associated
with their production of high titer autoantibody against cardiac
troponin I (71, 72). Cardiac troponin I auto antibodies have yet
to be validated as a biomarker for cardiac irAEs.
Brain-type natriuretic peptide (BNP): BNP and N-terminal
pro-brain natriuretic peptide (NT-proBNP) are standard
biomarkers used in clinical practice for the diagnosis and
management of heart failure. However, conclusions regarding
the role of natriuretic peptides for the risk analysis and diagnosis
of ICI cardiotoxicity remain undeﬁned. A retrospective studies
demonstrates an increased risk of ICI adverse event at B-type
natriuretic peptide (BNP) >100 pg/ml (HR: 2.65; 95% CI: 1.01 to
6.92; p = 0.047) (129).

outcomes in several cancers (125). Several studies have also
demonstrated PBC indices as predictive of ICI toxicities. For
example, a recent retrospective study showed that an absolute
lymphocyte count >820 at 2 weeks following nivolumab
initiation predicts the early onset of irAEs during in a 6-week
study period (126). Routinely available absolute lymphocyte
count may therefore be useful for identifying patients at risk of
early onset of ICI irAEs (126). Prospective studies are warranted
in this area.
Cytokines/Chemokines: Lim and colleagues recently proﬁled
the expression of 65 cytokines in 98 patients with melanoma treated
with PD-1 inhibitors alone or in combination with anti-CTLA-4
(127). Cytokine expression was found to strongly correlate with
irAEs warranting discontinuation of treatment and administration
of high-dose steroids. Eleven cytokines signiﬁcantly upregulated in
patients with severe irAEs were integrated into a single toxicity score
known as the CYTOX (cytokine toxicity) score. The most predictive
cytokines for ICI toxicities include G-CSF, GM-CSF, Fractalkine,
FGF-2, IFN-aplha2, IL12p70, IL1a, IL1B, IL1RA, IL2, and IL13
(127). The predictive utility of CYTOX score was conﬁrmed in an
independent validation cohort of 49 patients treated with
combination anti-PD-1 and anti-CTLA-4 (127). The utility of
CYTOX in predicting cardiac speciﬁc IrAEs has yet to be validated.

8 Roadmap to overcoming ICIinduced cardiac irAEs
8.1 Development and validating of
prognostic biomarkers for cardiac irAEs
As discussed, existing biomarkers for ICI cardiac irAEs have
relatively limited clinical data and/or lack extensive validation.
Biomarkers that are appropriately sensitive and speciﬁc to
therapy-induced injury could ﬁnd applications in long-term post
therapy management, subclinical toxicity detection, and pre therapy
risk stratiﬁcation for ICI therapy (131). Future biomarkers for
cardiac irAEs would be sensitive enough to detect subclinical
conditions but speciﬁc enough not to arise from the cancer itself.
Several have been proposed or are under investigation. Modern
capabilities in systems biology and genetics have enabled novel
techniques like high-through sensitive bioassays and multiomics
approaches (131). Currently proposed blood biomarkers include
high-sensitivity troponin levels (hs-TnI), microRNAs, C-reactive
protein, myeloperoxidase, galectin 3, interleukin family molecules
including ST2, matrix metalloproteinase, placental growth factor
(PlGF), growth differentiation factor 15, peripheral blood
mononuclear cell gene expression proﬁle, and human heart-type
fatty acid-binding protein (132) (133). Many of these biomarkers
are nonspeciﬁc to ICI as they have been detected at elevated levels
following other systemic therapies and cardiac radiotherapy (133,
134). Nevertheless, pre-treatment hs-Tnl levels (detected using a
modiﬁcation of the fourth-generation cTnT assay) at a cut-off of
14ng/L have been demonstrated to predict cardiovascular endpoints
and the progression of cardiac involvement in patients receiving
Nivolumab (135). It is notable in this regard that the Stanford
Cancer Institute has recently implemented surveillance for ICIassociated myocarditis with hs-TnI assay (136, 137). Another
predictive measure for cardiac irAEs severity following ICI
therapy may be the levels of certain microRNAs. Pre-clinical
studies have demonstrated an increased frequency and severity of
irAEs in murine models deﬁcient in miR-146a and studies of

7.2 Cardiac speciﬁc biomarkers
Cardiac Troponins: Cardiac troponin T (cTnT) and cardiac
troponin I (cTnI) are expressed exclusively in the myocardium.
They are elevated in 84% to 94% of patients with ICI
cardiotoxicity (including subclinical toxicities) (59, 105, 121).
cTnl is often preferred for cardiac IrAEs as cTnT and other
cardiac biomarkers such as CPK, BNP and/or proBNP may be
elevated in patients with concurrent pathologies associated with
ICI. For example, CPK is elevated in myositis which can be
immune mediated. (cTn) are released after cardiomyocytes
damage induced by various mechanisms such as ischemia,
inﬂammation, oxidative stress, or apoptosis. Several studies have
reported increased risk of ICI induced cardiac irAEs in patients
with elevated pre-treatment troponin. Mahmood and colleagues
compared the data of patients with and without myocarditis after
ICI treatment and found a four-fold increase in the risk of cardiac
irAEs for patients with troponin T (cTnT) ≥ 1.5 ng/ml (116, 121,
128). Another retrospective cohort study demonstrated a seven
fold risk of cardiac IrAEs in patient receiving ICIs with baseline
troponin >0.01 ng/ml (HR: 7.27; 95% CI: 2.72 to 19.43; p < 0.001)
(129). Although currently not recommended by the ASCO
updated guideline, there is a growing consensus to perform
baseline troponin measurements prior to initiating ICIs The
Heart Failure Association Cardio-Oncology Study Group and
the International Cardio-Oncology Society risk stratiﬁcation
guidelines for anticancer therapies recommends pretreatment
troponin determination (130).
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humans subjects have demonstrated an increased risk of severe
irAEs in patients on anti PD-1 therapy who have a single nucleotide
polymorphism (SNP) in miR-146a (138). MiR-34a is a critical
regulator of myocardial physiology that increases with age and has
been associated with cardiac senescence and dysfunction. Through
a variety of effects on the NF-kB and KLF4 signaling pathways miR34a also modulates T cell and macrophage functions such that
elevated levels may predispose patients to ICI-related cardiac
toxicities (67, 139–141). Further studies of baseline and posttreatment levels of these and other miRs are required to
substantiate the likelihood that these may have utility as
prognostic biomarkers for ICI cardiac irAEs.
Besides circulating biomarkers, functional and MRI imaging
markers have also been proposed to predict ICI toxicities.
Cardiac PET scans entail exposure to ionizing radiation, but
studies suggest they may be indicated for measuring long-term
ICI effects on the heart (142) . Advanced radioscopic imaging
techniques may also evaluate myocardial and vascular changes
at the molecular level (142). A recent retrospective study
identiﬁed septal late gadolinium enhancement as a possible
predictor of cardiac event in patients receiving ICIs (143). It will
be essential to contextualize any ﬁndings from circulatory and
imaging biomarkers with the speciﬁc mechanism of IrAEs. For
example, ICI-associated myocarditis biomarkers may detect
between the different phenotypes of myocarditis; lymphocytic
myocarditis is facilitated by proinﬂammatory TH17 cells and
CCR5, and giant cell myocarditis is thought to originate from
the autoantigen-triggered immunoproteasome, leading to CD4+
T cell recruitment and differentiation into TH1 and TH17
cells (64). Speciﬁc biomarkers along these immunological axes
may be candidates for novel biomarkers of ICI-speciﬁc
cardiac irAEs.

8.3 Novel prophylaxis and therapies for
cardiac irAEs
Current strategy for management of for ICI induced irAEs
are empirical as no studies have speciﬁcally addressed the issue.
There is potential for further development of anti-inﬂammatory
agents that are speciﬁc to the myocardium, which may be
administered prophylactically or in combination with current
ICIs to avert cardiac irAEs. Immune modulators which have
been shown in case reports or small case series to be effective in
reversing near-lethal ICI-myocarditis. Drugs which have been
investigated include tocilizumab (IL-6R antibody) (145),
alemtuzumab (anti-CD52) (17) (146), abatacept (CTLA-4
agonist) (147), ruxolitinib (JAK inhibitor) (148), inﬂiximab
(TNFa antibody) (149), tofacitinib (JAK inhibitor) (150),
mycophenolate moﬁtil (151), and antithymocyte globulin
(152), and IV immunoglobulin. (153) However, the
effectiveness of these therapies in ICI induced cardiac irAEs is
unclear and they are therefore only reserved for patients with
poor responses to corticosteroids. Further studies are needed to
better understand the clinical indication and safe dosage for
these drugs in patients with cardiac irAEs (154). For example,
the ongoing ATRIUM trial (Clinicaltrial.gov NCT05335928) is
being carried out to assess whether abatacept therapy, as
compared to placebo, is associated with a reduction in major
adverse cardiac events (MACE) among participants hospitalized
for ICI-induced myocarditis.
The recent ﬁndings that anti-PD-1 therapy induces
metabolic dysregulation associated with cardiac dysfunction
raises the prospect of metabolic intervention for cardiac irAEs
(70, 155) (81). Increased expression of TNFa is a notable
downstream effect of anti-PD1 therapy which can lead to
myocardial dysfunction via suppression of L-type calcium
channel and ryanodine receptor-2 activities in addition to its
pro-inﬂammatory activities. Michel and colleagues
demonstrated that TNFa blockade could avert the associated
subclinical manifestation of cardiac dysfunction due to anti-PD1
therapy in mice models without attenuating its anti-cancer
efﬁcacy. They hypothesize TNFa blockade may serve as a
novel cardioprotective treatment against ICI therapy (70, 81,
155, 156) . Such an outcome may be expected as inﬂammatory
mechanisms driven by TNFa are likely to have responsibility for
ICI-induced cardiotoxicity but be less important for T cellmediated anti-tumor immunity.

8.2 Utilization of immune checkpoint
inhibitors with reduced cardiotoxicity
A shift in focus to research and development of novel ICIs
which target antigens that are not shared amongst both the
myocardium and tumor in question, unlike the current targets
PD-1, PD-L1, CTLA-4, and LAG-3 may limit inﬂammatory
reactions against cardiomyocytes. New drugs under
investigation include anti-TIM-3 (T cell immunoglobulin and
mucin-containing protein 3), anti-VISTA (V-domain Ig
suppressor of T cell activation), anti-TIGIT, and anti-BTLA
antibodies (144). These targets have each been shown to restore
antitumor immunologic response in preclinical studies, and they
are currently under study in humans (144). Cardiotoxicity of these
agent are currently unknown. It is of utmost importance that these
ongoing human studies prioritize the assessment of adverse event
including cardiac toxicities in addition to cancer outcomes
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In conclusion, some advances have been made in
elucidating the pathologic mechanisms of ICI-associated
cardiac irAEs in recent years. Histopathologic grading
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criteria with diagnostic and prognostic values have been
developed but are yet to be standardized and universally
adopted. Potential strategies for mitigating ICI-associated
irAEs include: Developing and validating predictive
biomarkers; developing and utilizing less cardiotoxic ICIs;
administering prophylactically or in combination with ICIs
to avert cardiac irAEs; and prospective trials of known antiinﬂammatory agents with therapeutic beneﬁt in patients with
cardiac irAEs.
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